25,729 articles
TBIDFTECWCTC trial
TBIDFTECWCTC is a registered clinical trial (NCT07451678) testing eyelid cleansing with topical chlorhexidine wipes twice daily for four weeks against Demodex folliculorum blepharitis, assessing collarettes, erythema, and dry eye.
Tbx18 transduction
Tbx18 transduction delivers the T-box transcription factor 18 gene or mRNA to heart muscle to create a biological pacemaker, converting cardiomyocytes into sinoatrial-node-like cells; large-animal results exist but a 2026 AAV study found no genuine TBX18 pacemaker activity.
TCC trial
TCC trial (Tororo Child Cohort), NCT00527800, Interactions Between HIV and Malaria in African Children: Phase 3 UCSF-led cohort in Tororo, Uganda, 2007-2013, 351 children, testing TMP/SMX prophylaxis and artemether-lumefantrine versus dihydroartemisinin-piperaquine.
TCP (antiseptic)
TCP is a British over-the-counter liquid antiseptic of halogenated phenols 0.68% w/v and phenol 0.175% w/v, used for sore throats, mouth ulcers, and minor wounds; distinct from trichlorophenol.
tDCS trial (NCT02549560)
NCT02549560 (tDCS trial): University of Sao Paulo randomized, triple-masked trial of transcranial direct current stimulation, 2 mA over the right prefrontal cortex, to prevent postoperative cognitive dysfunction after cardiac surgery; 138 participants, registered 2015, completed November 2023.
tDCS trial (NCT05863494)
NCT05863494, "Toward Personalized Treatment of Chronic Pain Using tDCS Paired With Deep Learning," is a University of Arizona randomized double-blind sham-controlled trial of the tKIWI tDCS device in 40 adults with chronic pain, measuring pain, opioid use, vitals, and EEG.
tDCS trial (NCT06349369)
NCT06349369, an AIIMS Bhubaneswar randomized double-blind sham-controlled trial, tests tDCS (left DLPFC anode, left TPJ cathode, 10 days) on IL-6, TNF-alpha, and PANSS outcomes in chronic schizophrenia.
TDF trial
TDF trial (NCT05313477): a 48-week Phase 4 randomized trial at Mahidol University testing vitamin D2 plus calcium in TDF-treated chronic hepatitis B patients; PTH endpoint not met, but hip BMD was preserved versus controls.
TDI01 (oral ROCK2 inhibitor)
TDI01 (fimosudil, GV101, OV888) is an oral, highly selective ROCK2 inhibitor (IC50 10.31 nM) from Beijing Tide Pharmaceutical, in phase III trials for chronic graft-versus-host disease and idiopathic pulmonary fibrosis.
Teach-back method
The teach-back method is a communication technique in which a patient restates health instructions in their own words, letting the clinician verify understanding and correct misunderstandings.
Teaching Hospitals
Teaching hospitals, also called academic medical centers or university hospitals, combine patient care with accredited training of medical students, residents, and fellows plus research; over 1,000 exist in the US, employing 2.7 million people.
Team nursing
Team nursing is a hospital care delivery model in which a registered nurse leads a team caring for a shared group of patients. It was the dominant US hospital staffing model in the 1950s.
Team Nutrition
Team Nutrition is a USDA program, launched in 1995, that supports child nutrition programs through training, nutrition education, and promotion of healthy eating in schools.
Tear breakup time
Tear breakup time (TBUT) is a clinical eye test measuring the interval between a blink and the first dry spot on the cornea, a core measure in dry eye diagnosis.
Tear of lateral meniscus
Tear of the lateral meniscus, the outer knee shock-absorbing cartilage; distinguished from medial tears by popliteus tendon anatomy, lower MRI sensitivity, missed posterior root tears, and lower repair reoperation rates.
Tear of medial meniscus
Tear of medial meniscus: injury to the inner knee fibrocartilage, most often the posterior horn. Diagnosed by joint line tenderness, McMurray, Thessaly tests and MRI; treated by repair or meniscectomy, with repair better preserving joint health.
Tear Trough Deformity
Tear trough deformity (TTD, ICD-11 9A06.5), also called nasojugal groove: a sunken hollow between the lower eyelid and cheek from the inner canthus to the midpupillary line, caused by inherited anatomy or aging, treated with hyaluronic acid filler, fat grafting, fat repositioning, or implants.
TEARIAS trial
TEARIAS (NCT07818083) is a phase 3 Chinese multicenter randomized trial comparing tirofiban-enhanced antiplatelet therapy with dual antiplatelet therapy alone after stent-assisted coiling of ruptured intracranial aneurysms, with 90-day neurological prognosis as the primary endpoint and 622 planned participants.
Tears
Tears (lacrimal fluid) are secretions of the lacrimal, Meibomian, and conjunctival glands forming the tear film that lubricates, protects, and optically smooths the eye; types are basal, reflex, and emotional, and deficiency causes dry eye disease.
Tebentafusp
Tebentafusp (Kimmtrak), a gp100 x CD3 bispecific T-cell receptor fusion protein, approved 2022 for HLA-A*02:01-positive unresectable or metastatic uveal melanoma; first TCR bispecific and first mUM drug, with phase 3 overall survival benefit.
Tebipenem pivoxil
Tebipenem pivoxil (Utebzi) is an oral prodrug of the carbapenem tebipenem, FDA-approved June 17, 2026 as the first oral carbapenem, for complicated urinary tract infections including pyelonephritis in adults with limited oral options; notable for carnitine-depletion risk.
Tecarfarin
Tecarfarin (ATI-5923), an investigational oral vitamin K antagonist anticoagulant inhibiting VKORC1 like warfarin but metabolized by carboxylesterases instead of CYP450; phase 3, not approved.
Technetium (99mtc) apcitide
Technetium (99mTc) apcitide, also 99mTc-P280, brand AcuTect, is a technetium-99m-labeled cyclic peptide radiopharmaceutical binding platelet glycoprotein IIb/IIIa receptors, FDA-approved September 14, 1998 (NDA 020887) for imaging acute venous thrombosis and now discontinued.
Technetium bicisate
Technetium (99mTc) bicisate (ECD, Neurolite) is a lipophilic 99mTc radiopharmaceutical for brain SPECT perfusion imaging, FDA-approved in 1994 as an adjunct to CT/MRI for stroke localization, trapped in brain by esterase hydrolysis.
Technetium sestamibi
Technetium sestamibi (99mTc-MIBI, Miraluma) is a cationic technetium-99m SPECT radiopharmaceutical, FDA-approved December 1990, used for myocardial perfusion imaging, parathyroid adenoma localization, and second-line breast imaging; retained in mitochondria, 6-hour half-life, generator-produced.
Technetium tc 99m nofetumomab merpentan
Technetium (99mTc) nofetumomab merpentan, trade name Verluma, is a 99mTc-labeled Fab fragment of murine antibody NR-LU-10, a diagnostic radiopharmaceutical for staging small cell lung cancer, FDA-licensed in 1996 and later discontinued.
Technetium tc-99m trofolastat chloride
Technetium (99mTc) trofolastat chloride, also MIP-1404 or RoTecPSMA, is a urea-based PSMA-targeting technetium-99m SPECT/CT radiotracer for prostate cancer imaging, approved in the UK (2025) and Switzerland (2025).
Technetium teboroxime
Technetium teboroxime (Cardiotec, SQ30217), a BATO-class 99mTc myocardial perfusion SPECT tracer with 85-90% extraction and rapid washout; FDA-approved 1990, discontinued, abandoned clinically due to fast washout.
Teclistamab
Teclistamab (Tecvayli), a BCMA × CD3 bispecific antibody by Janssen, treats relapsed/refractory multiple myeloma; FDA accelerated approval October 2022, converted to traditional approval with daratumumab combination March 2026; MajesTEC-1 ORR 63%.
TECOS trial
TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin), NCT00790205, was a 14,735-patient randomized placebo-controlled trial showing sitagliptin noninferior for cardiovascular events (HR 0.98) and neutral for heart failure hospitalization in type 2 diabetes with established cardiovascular disease.